VVector Bio

VVector Bio, founded in 2019 and headquartered in Canada, specializes in providing Contract Development and Manufacturing Organization (CDMO) services for viral vector manufacturing. The company's slogan "Offering excellent CDMO services for viral vector manufacturing to support cell and gene therapy development" reflects its commitment to supporting advancements in cell and gene therapy. VVector Bio primarily focuses on the manufacturing of Lentivirus vectors and adeno-associated virus (AAV) from HEK-293 suspension cells, offering process and analytical development services. Additionally, the company provides manufacturing services for AAV from the baculovirus-insect cell system. Notably, VVector Bio extends its support to projects in the fields of vaccines and therapeutics, excelling in the manufacturing and process development of recombinant adenovirus vectors, enveloped virus-like particles (eVLPs), and recombinant proteins. The company's emphasis on innovation underscores its dedication to establishing more efficient, reproducible, and cost-effective manufacturing processes, ultimately aiming to make cell and gene therapy accessible to every patient in need. The company operates within the Biopharma, Biotechnology, and Clean Energy industries, positioning itself at the intersection of cutting-edge biopharmaceutical and sustainable energy technologies. As of now, there is no publicly available information regarding VVector Bio's last investment or the identity of its investors. Overall, VVector Bio's specialized CDMO services and its dedication to innovation make it an intriguing player in the rapidly advancing field of cell and gene therapy.